Compare KBR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBR | TMDX |
|---|---|---|
| Founded | 1901 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.6B |
| IPO Year | 2006 | 2019 |
| Metric | KBR | TMDX |
|---|---|---|
| Price | $37.22 | $114.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $53.14 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.3M | 857.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | 15.05 | ★ 382.18 |
| EPS | 3.21 | ★ 4.87 |
| Revenue | ★ $5,767,000,000.00 | $605,494,000.00 |
| Revenue This Year | $4.46 | $24.12 |
| Revenue Next Year | $5.21 | $18.69 |
| P/E Ratio | ★ $11.39 | $23.20 |
| Revenue Growth | 2.27 | ★ 37.13 |
| 52 Week Low | $36.33 | $62.42 |
| 52 Week High | $56.78 | $156.00 |
| Indicator | KBR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 35.22 |
| Support Level | N/A | $106.27 |
| Resistance Level | $45.05 | $120.28 |
| Average True Range (ATR) | 1.12 | 7.56 |
| MACD | -0.24 | -2.44 |
| Stochastic Oscillator | 15.57 | 12.40 |
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.